CH624674A5 - Process for the transposition of morphines to apomorphines - Google Patents
Process for the transposition of morphines to apomorphines Download PDFInfo
- Publication number
- CH624674A5 CH624674A5 CH1622177A CH1622177A CH624674A5 CH 624674 A5 CH624674 A5 CH 624674A5 CH 1622177 A CH1622177 A CH 1622177A CH 1622177 A CH1622177 A CH 1622177A CH 624674 A5 CH624674 A5 CH 624674A5
- Authority
- CH
- Switzerland
- Prior art keywords
- yield
- reaction
- prepared
- morphine
- transposition
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 230000017105 transposition Effects 0.000 title description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 36
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 20
- 235000011007 phosphoric acid Nutrition 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229960004046 apomorphine Drugs 0.000 claims description 13
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical class C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 10
- 229960005181 morphine Drugs 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- DZUOQMBJJSBONO-CQSZACIVSA-N (6ar)-10-methoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-11-ol Chemical compound CN1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(OC)C(O)=C13 DZUOQMBJJSBONO-CQSZACIVSA-N 0.000 claims description 3
- MHPQCGZBAVXCGA-GFCCVEGCSA-N (6ar)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Chemical group N1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(O)C(O)=C13 MHPQCGZBAVXCGA-GFCCVEGCSA-N 0.000 claims description 3
- BTGAJCKRXPNBFI-OAHLLOKOSA-N (8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-13,14-diol Chemical compound C([C@H]1N(CCC)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 BTGAJCKRXPNBFI-OAHLLOKOSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052753 mercury Inorganic materials 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical group C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 229950006134 normorphine Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- -1 cyclobu-tyle Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- BXKJGGVENHTVBF-JFDOVZFRSA-N (4r,4ar,7s,7ar,12bs)-3-(2-phenylethyl)-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical group C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@@H]1C=C[C@@H]3O)CN2CCC1=CC=CC=C1 BXKJGGVENHTVBF-JFDOVZFRSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75788877A | 1977-01-10 | 1977-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH624674A5 true CH624674A5 (en) | 1981-08-14 |
Family
ID=25049636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1622177A CH624674A5 (en) | 1977-01-10 | 1977-12-29 | Process for the transposition of morphines to apomorphines |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS5387359A (en, 2012) |
| AU (1) | AU510976B2 (en, 2012) |
| BE (1) | BE862389A (en, 2012) |
| CA (1) | CA1092122A (en, 2012) |
| CH (1) | CH624674A5 (en, 2012) |
| DE (1) | DE2758954A1 (en, 2012) |
| DK (1) | DK584077A (en, 2012) |
| FR (1) | FR2376847A1 (en, 2012) |
| GB (1) | GB1566049A (en, 2012) |
| IE (1) | IE45922B1 (en, 2012) |
| LU (1) | LU78790A1 (en, 2012) |
| NL (1) | NL7714227A (en, 2012) |
| NZ (1) | NZ185799A (en, 2012) |
| SE (1) | SE7713456L (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3171561D1 (en) * | 1980-05-08 | 1985-09-05 | Univ Northeastern | N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same |
| WO1990012574A1 (en) * | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
| GB201915911D0 (en) * | 2019-11-01 | 2019-12-18 | Johnson Matthey Plc | Process |
-
1977
- 1977-11-22 GB GB4862177A patent/GB1566049A/en not_active Expired
- 1977-11-22 CA CA291,508A patent/CA1092122A/en not_active Expired
- 1977-11-23 IE IE237377A patent/IE45922B1/en unknown
- 1977-11-28 SE SE7713456A patent/SE7713456L/xx not_active Application Discontinuation
- 1977-11-28 NZ NZ18579977A patent/NZ185799A/xx unknown
- 1977-11-28 AU AU31013/77A patent/AU510976B2/en not_active Expired
- 1977-12-21 NL NL7714227A patent/NL7714227A/xx not_active Application Discontinuation
- 1977-12-28 FR FR7739473A patent/FR2376847A1/fr active Granted
- 1977-12-28 BE BE1008611A patent/BE862389A/xx unknown
- 1977-12-29 CH CH1622177A patent/CH624674A5/fr not_active IP Right Cessation
- 1977-12-29 JP JP15869177A patent/JPS5387359A/ja active Pending
- 1977-12-29 LU LU78790A patent/LU78790A1/xx unknown
- 1977-12-29 DK DK584077A patent/DK584077A/da unknown
- 1977-12-30 DE DE19772758954 patent/DE2758954A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DK584077A (da) | 1978-07-11 |
| BE862389A (fr) | 1978-06-28 |
| AU510976B2 (en) | 1980-07-24 |
| FR2376847A1 (fr) | 1978-08-04 |
| LU78790A1 (en, 2012) | 1978-07-11 |
| NZ185799A (en) | 1979-12-11 |
| AU3101377A (en) | 1979-06-07 |
| SE7713456L (sv) | 1978-07-11 |
| FR2376847B1 (en, 2012) | 1980-08-22 |
| IE45922B1 (en) | 1982-12-29 |
| NL7714227A (nl) | 1978-07-12 |
| IE45922L (en) | 1978-07-10 |
| GB1566049A (en) | 1980-04-30 |
| CA1092122A (en) | 1980-12-23 |
| JPS5387359A (en) | 1978-08-01 |
| DE2758954A1 (de) | 1978-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH639070A5 (fr) | 4-(di-n-propyl)amino-1,3,4,5-tetrahydrobenzo(cd)indole et composition pharmaceutique en contenant. | |
| EP0010460B1 (fr) | Nouveaux dérivés de pyrrolidine-2-méthanol, procédé pour leur préparation et médicaments les contenant | |
| EP0030528B1 (fr) | Procédé pour la fixation de groupes alkyles, aralkyles ou cycloalkyles sur une chaîne carbonée portant un groupe fonctionnel | |
| CH624674A5 (en) | Process for the transposition of morphines to apomorphines | |
| EP0053964B1 (fr) | Médicaments à base de dérivés de (quinolyl-4)-1 éthanol ou propanol, nouveaux dérivés de (quinolyl-4)-1 éthanol ou propanol et procédés pour leur préparation | |
| EP0089894B1 (fr) | (Benzimidazolyl-1)-1,N-((hydroxy-4 méthoxy-3 phényl)-2 hydroxy-2 éthyl) amino-3 butane et ses sels et hydrates à activité bêta-adrénergique, leurs applications thérapeutiques, et procédé pour les préparer | |
| EP0443918B1 (fr) | Nouveaux dérivés de la 20,21-dinoréburnaménine, leur procédé de préparation et les nouveaux intermédiaires ainsi obtenus, leur application comme médicaments et les compositions les renfermant | |
| EP0007834A1 (fr) | Procédé de préparation d'alpha aminoacides optiquement actifs et leurs dérivés | |
| EP0147312A2 (fr) | Nouvelles imidazo /1,2-c/ pyrimidines et leurs sels, leur procédé de préparation, leur application à titre de médicaments et les compositions les renfermant | |
| EP0486385A1 (fr) | Dérivés d'imidazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CH622795A5 (en, 2012) | ||
| EP0007828B1 (fr) | Procédé de préparation d'esters d'alcoyle de l'acide dl-cis chrysanthémique | |
| FR2560873A1 (fr) | Medicaments a base de derives de la piperidine, nouveaux derives de la piperidine et leurs procedes de preparation | |
| EP0065907B1 (fr) | ((Tétra- et hexahydro pyridyl-4)-2 éthyl)-3 indoles et leur utilisation comme médicaments | |
| CH646146A5 (fr) | Derive du 1alpha,25-dihydroxy cholecalciferol et son procede de preparation. | |
| EP0082040B1 (fr) | Dérivés de diaza-3,7a cyclohepta(j,k)fluorènes, leur préparation et leur application en thérapeutique | |
| CH621784A5 (en, 2012) | ||
| EP0927152B1 (fr) | Procede de preparation de benzylalcools alpha-substitues optiquement actifs | |
| EP1131293A1 (fr) | Derives de 1-aminoethylquinoleine pour le traitement de l'incontinence urinaire | |
| EP3592753B1 (fr) | Nouvelle composition d'isomeres du 7,9-dodécadiényl-1-acétate et son procede de fabrication | |
| CA1192909A (fr) | Procede d'epimerisation d'acides trans chrysanthemiques et nouveaux intermediaires obtenus | |
| EP0065908A1 (fr) | ((Alkyl- et alcényl-3 pipéridyl-4)-2 éthyl)-3 indoles et leur utilisation comme médicaments | |
| BE864430R (nl) | Nouveaux derives d'amidoxime, leur procede de preparation ainsi que les compositions therapeutiques les contenant | |
| CA1116089A (fr) | Compositions pharmaceutiques comprenant des medicaments a base de derives de la quinoleine | |
| BE882024A (fr) | Nouvelles chano-e-homovincamones, leur procede de preparation et leur utilisation en tant que medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |